

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 February 2002 (21.02.2002)

PCT

(10) International Publication Number
WO 02/014356 A3

(51) International Patent Classification⁷: **A61K 38/18**,
A61P 25/00, 9/00

(21) International Application Number: PCT/EP01/09209

(22) International Filing Date: 9 August 2001 (09.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/637,962 11 August 2000 (11.08.2000) US

(71) Applicant (*for all designated States except US*): **ELANEX PHARMA (IOM) LTD.** [US/US]; Companies House, Tower Street, Ramsey, Isle of Man (US).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **THOMPSON, Lawrence, H.** [US/US]; 177 No. USA HWA ONE, Suite 305, US-Tequesta, Fl. 33469 (US).

(74) Agent: **SHNEIDERS & BEHRENDT**; Huestraße 23, 44787 Bochum (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
30 January 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPEUTIC USE OF A RECOMBINANT ERYTHROPOIETIN HAVING HIGH ACTIVITY AND REDUCED SIDE EFFECTS

(57) Abstract: The invention discloses several novel therapeutic properties and methods of treatment using the recombinant erythropoietin prepared by expression from the Apa I restriction fragment of human genomic erythropoietin DNA transformed into baby hamster kidney cells (BHK) according to U.S. Patent No. 5,688,697 to Powell. This recombinant erythropoietin designated herein as Epoetin Omega is shown to possess several unexpected and superior qualities over other recombinant erythropoietins such as those designated Epoetin Alfa and Beta which are prepared from genomic or cDNA expressed in Chinese Hamster Ovary (CHO) according to U.S. Patent Nos. 4,703,008 and 5,955,422 to Lin. The superior properties of Epoetin Omega include, but are not limited to, a much higher potency, a much more rapid response (*i.e.* no latency), longer effective serum levels, much lower antigenicity in human subjects, therapeutic activity in subjects non-responsive to the other epoetins, fewer adverse side effects such as incidents of thrombosis, reduced nausea, reduced pain at the site of injection, reduction in body pain, and most significantly, the absence of, or reduced risk of, increased blood pressure or hypertension. These novel properties provide for novel therapeutic methods including, treatment of anemia and treatment of conditions other than anemia such as fatigue or vascular pain, treatment in patients adversely effected by hypertension such as patients with heart conditions or at increased risk of thrombosis, treatment in oncology settings with and without chemotherapy or radiation therapy, and treatment with novel dosing regimens that include much lower doses and lower administration frequencies of as few as once per week or less.



WO 02/014356 A3

INTERNATIONAL SEARCH REPORT

Int onal Application No

PCT/EP 01/09209

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/18 A61P25/00 A61P9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	H. LUDWIG : "Epoetin in cancer-related anaemia" NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 14, no. suppl 2, February 1999 (1999-02), pages 85-92, XP002219608 the whole document -/--	1,4, 11-15,47

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

6 November 2002

Date of mailing of the international search report

19/11/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ryckebosch, A

INTERNATIONAL SEARCH REPORT

Int l onal Application No

PCT/EP 01/09209

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1990 CAN ERYTHROPOIETIN STUDYGROUP: "ASSOCIATION BETWEEN RECOMBINANT HUMAN ERYTHROPOIETIN AND QUALITY OF LIFE AND EXERCISE CAPACITY OF PATIENTS RECEIVING HEMODIALYSIS" Database accession no. PREV199089118498 XP002219609 abstract & BRITISH MEDICAL JOURNAL, vol. 300, no. 6724, 1990, pages 573-578, ISSN: 0959-8138 ---	1
A	WO 00 24893 A (AMGEN INC) 4 May 2000 (2000-05-04) page 4, line 30 -page 7, line 10; claims ---	1-47
A	WO 88 00241 A (UNIV WASHINGTON) 14 January 1988 (1988-01-14) page 2, line 6 - line 14; claims ---	1-47
P,X	S. MILUTINOVIC ET AL.: "Erythropoietin-induced hypertension in dialyzed uremics is influenced by glycosylation patterns of the molecule." NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 16, no. 6, June 2001 (2001-06), page A91 XP008010133 abstract ---	29-36,47
P,X	S. MILUTINOVIC ET AL.: "Differences in glycosylation structures have an important impact on potency and pharmacokinetics of erythropoietin (EPO) in dialyzed uremics." NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 15, no. 9, September 2000 (2000-09); page A156 XP008010132 abstract -----	29-36,47

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/09209

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0024893	A	04-05-2000	AU 1124100 A	15-05-2000
			CA 2345882 A1	04-05-2000
			CN 1346369 T	24-04-2002
			EP 1123313 A2	16-08-2001
			HU 0103920 A2	28-02-2002
			JP 2002528465 T	03-09-2002
			WO 0024893 A2	04-05-2000
<hr/>				
WO 8800241	A	14-01-1988	AT 76431 T	15-06-1992
			AU 611088 B2	06-06-1991
			AU 7475787 A	07-01-1988
			BR 8703269 A	15-03-1988
			CN 87104424 A , B	27-04-1988
			DE 3779206 D1	25-06-1992
			DK 309387 A	28-12-1987
			EP 0255231 A1	03-02-1988
			ES 2037083 T3	16-06-1993
			FI 880899 A , B ,	26-02-1988
			GR 3004707 T3	28-04-1993
			JP 63126488 A	30-05-1988
			KR 9709935 B1	19-06-1997
			NO 880863 A	26-04-1988
			PT 85193 A , B	01-07-1987
			US 2002137145 A1	26-09-2002
			WO 8800241 A1	14-01-1988
			US 5688679 A	18-11-1997
			US 2002045255 A1	18-04-2002